Biogen announced two-year data from the Phase 2 CELIA study showing that its investigational therapy diranersen slowed clinical decline in early Alzheimer's disease.
Benzinga
1 story shown
Biogen announced two-year data from the Phase 2 CELIA study showing that its investigational therapy diranersen slowed clinical decline in early Alzheimer's disease.